Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
zamzetoclax (GS-9716) Monotherapy and Combination Therapy in Solid Malignancies
NCT05006794Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of zamzetoclax in Solid malignancy (6 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Patients Experiencing Dose-Limiting Toxicities at 28 days and Percentage of Patients Experiencing Adverse Events. Started Sep 2021; status: terminated.
02
Drugs
zamzetoclax
03
Conditions
Solid malignancy
Beyond the preview
Go deeper on NCT05006794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006794.